By Juliet Umeh

Nigeria is on the verge of a scientific renaissance, one that could position the country as a biotech trailblazer on the African continent and beyond. Building upon a rich academic legacy, a strong talent pool, and an urgent call from global policymakers for more diverse clinical trials, Nigeria’s biotech sector is ready for takeoff—provided we make strategic moves now. In this Vanguard exclusive with Juliet Umeh, Dr. Precious Azino Usuemerai—a pharmacist-entrepreneur whose mentors collectively represent decades of experience—outlines an all-encompassing blueprint for Nigeria’s biotech revolution.

Dr. Usuemerai’s journey spans the rigorous PharmD program at the University of Benin (UNIBEN), on-the-ground pharma work during COVID-19 that saved thousands of lives, plus high-level immersion at the University of Chicago Booth School of Business and a Genentech internship in San Francisco. He merges practical Nigerian insights with global best practices, painting a vivid roadmap relevant to policymakers, CEOs, global pharma, academics, and diaspora professionals alike. Excerpts:

How did your PharmD journey at the University of Benin and your work in Nigeria’s pharmaceutical sector shape your biotech vision?

UNIBEN’s PharmD program was a rare phenomenon in West Africa at the time, demanding extraordinary clinical depth and problem-solving skills. After graduating, I spent six years in Nigeria’s pharma sector, including the launch of a COVID-19 drug distribution startup that delivered care to thousands—some estimates put the direct benefit at over 10,000 patients.

That frontline experience revealed glaring infrastructure gaps and daunting regulatory hurdles. In search of sustainable solutions, I pursued an MBA at the University of Chicago Booth School of Business—consistently ranked among the top by U.S. News & World Report. There, under Professor Meadow Scott, I studied biotech PIPE deals and recognized how U.S. venture ecosystems fuel innovation. An internship at Genentech in San Francisco showed me firsthand how an integrated pipeline—where academia, industry, and regulators collaborate—expedites life-saving therapies.

By combining these insights with mentorship from industry veterans, I became convinced that Nigeria, too, has the potential to catalyze a biotech renaissance. But it requires bold policy reforms, investment, and unity across stakeholders.

The United States is pushing forward with the Inflation Reduction Act, the Biosecure Act, and a heightened emphasis on diverse clinical trials. How does this shape the biotech horizon for Nigeria?

These policies echo a global redirection of resources. The Inflation Reduction Act allocates massive funding toward research grants, green technology, and future-focused pharma developments. The Biosecure Act aims to bolster the U.S.’s capacity for pandemic defense, naturally sparking R&D expansions in diagnostics, therapeutics, and vaccine technologies.

Diversity in clinical trials is another game-changer. Regulatory bodies like the FDA are insisting on representative trial populations to ensure new therapies are genuinely effective for all demographics. South Africa currently outpaces us in hosting global trials, earning crucial revenues and building clinical-research expertise. But with over 220 million people, Nigeria can surpass them—if we act decisively.

Let’s get specific. Where do we stand, and how big is this missed opportunity?

Multiple data points illustrate our gap. A World Bank report notes Nigeria consistently invests under 0.5% of its GDP in R&D, trailing even the African Union’s recommended 1%. Contrast this with South Africa, which hovers around 0.8–1% of GDP. Deloitte estimates emerging African markets could command $1.5–$3 billion in outsourced clinical trials by 2030. Nigeria’s share is comparatively minuscule, partly due to slow regulatory approvals. Companies like Fidson, Emzor, and May & Baker have excelled in generics and basic drug manufacturing, but advanced biotech product development or large-scale clinical trial hosting remains elusive. The Nigeria Medical Association suggests a steady outflow of our brightest medical and scientific minds, lured by better-equipped labs abroad.

Yet the successes are not zero. During the height of COVID-19, the Nigerian Institute of Medical Research (NIMR) fast-tracked some groundbreaking diagnostic kits, and NIPRD made progress formulating phytomedicine research. These sparks prove that with adequate support and synergy, we can innovate at a global standard.

Could you clarify the role of the African Development Bank’s African Pharmaceutical Technology Foundation (APTF)? How does that align with biotech expansion?

The APTF is the AfDB’s strategic initiative to strengthen Africa’s pharmaceutical manufacturing and technology transfer capabilities. Although it’s not labeled a “biotech institute,” today’s pharmaceuticals heavily rely on biotechnological processes.

APTF can bridge gaps between African manufacturers and global pharma, giving local producers a chance to license and produce vaccines, biosimilars, and advanced therapeutics; Offer Policy Blueprints: Harmonize regulations across African countries, streamlining approvals and encouraging continent-wide trials;  Attract FDI: Global companies will be more willing to invest if they see Africa has aligned standards and stable partnerships.

For Nigeria specifically, the APTF provides an avenue to modernize cGMP facilities, streamline NAFDAC regulations, and form collaborative agreements with industry titans. Countries like Morocco and Rwanda are already engaging the APTF to bolster local vaccine manufacturing. We risk losing out if we don’t negotiate robust roles for Nigeria soon.

You referenced sparks of innovation. Do you have a standout example to inspire stakeholders?

Yes—take Professor Oyewale Tomori, a globally recognized virologist and former Vice-Chancellor at Redeemer’s University. Though he’s been a vocal scientific leader on viral diseases, the institutional frameworks for biotech translation in Nigeria remain inadequate. If a streamlined system existed, his expertise (and that of dozens more like him) could have spurred local vaccine R&D programs equivalent in caliber to those abroad.

We also have smaller biotech ventures forming in Lagos’ Yaba tech cluster, focusing on rapid diagnostics for tropical diseases. With the right seed funding and incubator supports—mirroring India’s BIRAC program—such startups could grow exponentially. This is exactly the sort of synergy we need to scale.

Let’s get prescriptive. If Nigeria’s President, top ministers, and CEOs read this, what do you propose?

Short-Term (1–3 Years) –  Adopt an e-submission system at NAFDAC, cutting approval times by up to 50%;  Offer tax breaks to global sponsors choosing Nigeria for large Phase II/III trials; A 10–15% credit for biotech R&D costs; Government and private banks jointly pool capital. This was a key factor in India’s biotech rise through BIRAC; Kickstart TTOs at UNIBEN, UNILAG, UI, ABU, to patent local discoveries and spin them into startups;  Incubation programs modeled on Yaba’s co-creation hub but dedicated to biotech.

Long-Term (5–10 Years) –  Negotiate co-development deals or manufacturing licenses for complex biologics (e.g., mRNA vaccines) under the APTF umbrella; Adopt a unified regulatory framework across ECOWAS, forming a mini “single market” for clinical trials; Special Economic Zones (SEZs) in Lagos, Abuja, or Ogun State with cGMP-certified parks; Encourage global pharma to set up finishing-and-filling lines for vaccines, creating thousands of skilled jobs.

Reverse Brain Drain – Offer diaspora packages for top scientists—research grants, lab space, and tenured positions to direct cutting-edge programs; Partnerships with institutions like the Nigeria Institute of Medical Research (NIMR) for advanced therapy labs.

Could you distill the potential impact?

Certainly. If Nigeria claims even 20% of the African market for outsourced clinical trials, that’s anywhere from $300–$600 million in annual revenue by 2030, per the Deloitte forecast. cGMP vaccine or biosimilar production could bring in $1–$2 billion in exports across West Africa, based on World Health Organization (WHO) market evaluations. Each new biomanufacturing facility can create hundreds of high-skill jobs—lab technicians, quality assurance officers, data scientists—and catalyze a broader network of tens of thousands in supporting sectors.

Socially, we’d enhance healthcare access, drastically reduce the need for imported medications, and gain a robust firewall against future pandemics.

Dr. Usuemerai, you’ve sketched a bold yet achievable vision for Nigeria’s biotech future. Any closing thoughts?

The time for half-measures is over. President Bola Tinubu and the Federal Executive Council need to treat biotech development as a nation-building exercise. Universities should embrace industry partnerships and fast-track patent commercialization. Private investors must see the colossal ROI in biotech, not just short-term gains from generic imports. And the African Pharmaceutical Technology Foundation is a golden opportunity to secure technology transfer deals that usher Nigeria into manufacturing biologics and vaccines at scale.

We owe it to every Nigerian—current and future—to establish a thriving biotech ecosystem. This is how we protect our citizens from health crises, create high-value jobs, and stand tall on the international stage.

Dr. Precious Azino Usuemerai, thank you for your invaluable insights. May this interview serve as a rallying cry for all stakeholders—government, academia, investors, and healthcare professionals—to unify around this critical mission. The data is there, the blueprint is laid. Now it’s about execution.

Thank you. I’m convinced that if we unite with common purpose and urgency, Nigeria can evolve from a biotech latecomer to a global heavyweight—redefining health security and economic prosperity across Africa.

Key Takeaways & Next Steps

1. Sovereign Biotech Fund: Seeded by government and private banks, fueling early-stage R&D and accelerating local biotech startups.

2. Fast-Track Regulatory System: Digitize and expedite NAFDAC approvals, aligning with global best practices for clinical trials.

3. University & Industry Synergy: Establish powerful tech-transfer offices (TTOs) in leading universities (UNIBEN, UNILAG, UI, ABU) to patent discoveries and nurture spin-offs.

4. APTF Engagement: Secure advanced pharma technology licenses and manufacturing deals via the African Pharmaceutical Technology Foundation.

5. Encourage Diaspora Returns: Offer well-structured diaspora incentives—funded labs, academic positions, biotech campus infrastructure—to reverse brain drain.